MONOPRIL
LOE ApproachingNDAORALTABLET
Approved
May 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MONOPRIL is an oral small-molecule tablet approved in 1991 by Bristol Myers Squibb. The specific indication and mechanism of action are not provided in available data. This is a mature NDA product approaching loss of exclusivity.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting a small-to-mid-sized commercial team focused on lifecycle management and generic defense strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MONOPRIL offers career experience in mature product management, generic defense, and lifecycle strategy within a large pharma organization (Bristol Myers Squibb). However, limited active job postings and approaching LOE suggest this may be a consolidation or support role rather than a growth opportunity.
Brand ManagerField Sales Representative
Worked on MONOPRIL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.